News

The Dose Podcast - Episode 2 "Translating the UNHLM Commitments into Action"


19 Dec 2018
by Working Group

Episode 2: "Translating the UNHLM Commitments into Action: Ensuring Investment in TB R&D to eliminate TB" 

The second episode of The Dose Podcast will focus on the first ever High-Level Meeting on Tuberculosis held by the United Nations General Assembly and the commitments made there to fight TB. The High-Level Meeting is only the fifth time that the UN in its history has called for a high-level meeting devoted to a health issue.  This podcast will highlight the outcomes resulting from the UNHLM, consider how we can hold countries accountable to their commitments, as well as drive the momentum in development of new TB therapies, vaccines and diagnostics.

Moderator: Bobby Ramakant, Citizen News Service

Speaker: Honorable Nick Herbert, Member of Parliament for Arundel and South Downs in the UK.

Speaker: Blessi Kumar, CEO of the Global Coalition of TB Activists

Listen on Soundcloud: https://soundcloud.com/user-87209407/the-does-podcast-episode-2-translating-the-unhlm-commitments-into-action

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...